Trial reportThe American journal of clinical nutrition2010
The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid.
Trial report in The American journal of clinical nutrition, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00753818 (Developmental Effects of Infant Formula Supplemented With LCPUFA), which is not on this map. Cited by 93 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Developmental Effects of Infant Formula Supplemented With LCPUFA
Who cites it
93 citing papers in PubMed, 10 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Could early life DHA supplementation benefit neurodevelopment? A systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Human Milk Macronutrients and Child Growth and Body Composition in the First Two Years: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2024Pooled it
- Supplementation of Infant Formula and Neurodevelopmental Outcomes: a Systematic Review.Current nutrition reports · 2022Pooled it
- VEP estimation of visual acuity: a systematic review.Documenta ophthalmologica. Advances in ophthalmology · 2021Pooled it
- Pooled it
- Effects of LC-PUFA Supplementation in Patients with Phenylketonuria: A Systematic Review of Controlled Trials.Nutrients · 2019Pooled it
- n-3 Fatty Acid Supplementation in Mothers, Preterm Infants, and Term Infants and Childhood Psychomotor and Visual Development: A Systematic Review and Meta-Analysis.The Journal of nutrition · 2018Pooled it
- Long chain polyunsaturated fatty acid supplementation in infants born at term.The Cochrane database of systematic reviews · 2017Pooled it
- Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy.The Cochrane database of systematic reviews · 2016Pooled it
- Pooled it
- Prenatal docosahexaenoic acid supplementation has long-term effects on childhood behavioral and brain responses during performance on an inhibitory task.Nutritional neuroscience · 2022Trial
- Maternal Factors Associated with Levels of Fatty Acids, Specifically n-3 PUFA during Pregnancy: ECLIPSES Study.Nutrients · 2021Trial
- Trial
- Trial
- Maternal Docosahexaenoic Acid Status during Pregnancy and Its Impact on Infant Neurodevelopment.Nutrients · 2020Trial
- Trial
- Prenatal maternal docosahexaenoic acid intake and infant information processing at 4.5mo and 9mo: A longitudinal study.PloS one · 2019Trial
- Long-chain polyunsaturated fatty acid supplementation in the first year of life affects brain function, structure, and metabolism at age nine years.Developmental psychobiology · 2019Trial
- An infant formula containing dairy lipids increased red blood cell membrane Omega 3 fatty acids in 4 month-old healthy newborns: a randomized controlled trial.BMC pediatrics · 2018Trial
- Trial
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe range of human milk docosahexaenoic acid (DHA) concentrations worldwide is much broader than the range explored in randomized clinical trials to date.
objectiveThe primary objective was to determine the effect of 4 amounts of DHA supplementation on the visual acuity of formula-fed infants at 12 mo of age. Secondary objectives were to evaluate visual acuity maturation, red blood cell fatty acids, tolerance, anthropometric measures, and adverse events.
designThis double-masked, randomized trial was conducted at 2 sites (Dallas and Kansas City). Three hundred forty-three healthy, term, formula-fed infants were enrolled at 1-9 d of age and were randomly assigned to be fed 1 of the following 4 infant formulas containing equivalent nutrient amounts, except for long-chain polyunsaturated fatty acids: control (0% DHA), 0.32% DHA, 0.64% DHA, or 0.96% DHA; DHA-supplemented formulas also provided 0.64% arachidonic acid. Visual acuity was measured by visual evoked potentials in 244 infants who completed the 12-mo primary outcome examination.
resultsInfants fed control formula had significantly poorer visual evoked potential visual acuity at 12 mo of age than did infants who received any of the DHA-supplemented formulas (P < 0.001). There were no significant differences in visual evoked potential visual acuity between the 3 amounts of DHA supplementation for either site at any age tested.
conclusionsDHA supplementation of infant formula at 0.32% of total fatty acids improves visual acuity. Higher amounts of DHA supplementation were not associated with additional improvement of visual acuity. This trial was registered at clinicaltrials.gov as NCT00753818.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.